Trending NewsTrending NewsNASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis $14.51 +0.01 (+0.07%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$14.55 +0.04 (+0.25%) As of 09/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RARE alerts:Sign Up Key Stats Today's Range$14.07▼$15.0750-Day Range$12.88▼$33.2252-Week Range$12.73▼$39.89Volume13.33 million shsAverage Volume5.41 million shsMarket Capitalization$1.43 billionP/E RatioN/ADividend YieldN/APrice Target$34.42Consensus RatingHold Company Overview Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options. Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia. The company also maintains a pipeline of investigational medicines, including gene therapies and other biologic treatments for rare diseases. Founded in 2010, Ultragenyx is headquartered in Novato, California, and serves patients through commercial operations and partnerships in the United States and international markets. The company was founded by Emil Kakkis, M.D., Ph.D., who continues to serve as its chief executive officer. Ultragenyx has also worked with other pharmaceutical companies to support the development, commercialization and distribution of its therapies.AI Generated. May Contain Errors. Read More Ultragenyx Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreRARE MarketRank™: Ultragenyx Pharmaceutical scored higher than 68% of companies evaluated by MarketBeat, and ranked 226th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.48, and is based on 1 strong buy rating, 9 buy ratings, 10 hold ratings, and 1 sell rating.Upside PotentialUltragenyx Pharmaceutical has a consensus price target of $34.42, representing about 137.2% upside from its current price of $14.51.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ultragenyx Pharmaceutical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($3.98) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ultragenyx Pharmaceutical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.34% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.74 News SentimentUltragenyx Pharmaceutical has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 32 news articles for Ultragenyx Pharmaceutical this week, compared to 11 articles on an average week.Search Interest43 people have searched for RARE on MarketBeat in the last 30 days. This is an increase of 4,200% compared to the previous 30 days.MarketBeat Follows20 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 1,900% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,663.00 in company stock.Percentage Held by Insiders5.20% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ultragenyx Pharmaceutical's insider trading history. Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RARE Stock News HeadlinesLeerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)2 hours ago | theglobeandmail.comUltragenyx Pharmaceutical (RARE) Receives a Buy from Canaccord Genuity2 hours ago | theglobeandmail.com“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days. | Chaikin Analytics (Ad)How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI2 hours ago | finance.yahoo.comUltragenyx Wins FDA Approval For FAYUVI In Pediatric MPS IIIASeptember 18 at 10:11 AM | rttnews.comUltragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A TranscriptSeptember 18 at 3:00 AM | seekingalpha.comUltragenyx Shares Rise After FDA Approval for Sanfilippo Syndrome TreatmentSeptember 17 at 11:42 PM | finance.yahoo.comUltragenyx Pharmaceutical (NASDAQ:RARE) CAO Theodore Alan Huizenga Sells 1,283 Shares of StockSeptember 16, 2026 | insidertrades.comSee More Headlines RARE Stock Analysis - Frequently Asked Questions How have RARE shares performed this year? Ultragenyx Pharmaceutical's stock was trading at $23.00 at the start of the year. Since then, RARE shares have decreased by 36.9% and is now trading at $14.51. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its earnings results on Tuesday, August, 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating analysts' consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical's revenue for the quarter was up 28.5% on a year-over-year basis. Read the conference call transcript. When did Ultragenyx Pharmaceutical IPO? Ultragenyx Pharmaceutical (RARE) raised $112 million in an initial public offering on Friday, January 31st 2014. The company issued 5,760,369 shares at $19.00-$20.00 per share. Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's top institutional investors include BlackRock Inc. (10.82%), Wellington Management Group LLP (1.27%), Bank of America Corp DE (1.16%) and Jefferies Financial Group Inc. (0.94%). Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, Eric Crombez, John Richard Pinion, Howard Horn, Karah Herdman Parschauer, Erik Harris, Theodore Alan Huizenga, Shehnaaz Suliman, Corazon (Corsee) D Sanders and Matthew K Fust. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/04/2026Today9/20/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, RARE's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RARE CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,371Year Founded2010Price Target and Rating Average Price Target for Ultragenyx Pharmaceutical$34.42 High Price Target$90.00 Low Price Target$16.00 Potential Upside/Downside+137.2%Consensus RatingHold Rating Score (0-4)2.48 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($5.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$575 million Net Margins-81.79% Pretax Margin-81.18% Return on Equity-1,024.42% Return on Assets-44.40% Debt Debt-to-Equity RatioN/A Current Ratio1.73 Quick Ratio1.56 Sales & Book Value Annual Sales$673 million Price / Sales2.13 Cash FlowN/A Price / Cash FlowN/A Book Value($0.83) per share Price / Book-17.48Miscellaneous Outstanding Shares98,590,000Free Float93,462,000Market Cap$1.43 billion OptionableOptionable Beta0.31 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:RARE) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RARE Stock Alerts